Home » Newsletters » BioWorld Science

BioWorld Science

May 16, 2012

View Archived Issues

NKP-2235 shows unique cytotoxicity profile and synergistic activity with other anticancer agents

Recombinant vectors targeting NY-ESO-1 assessed in phase II trials

First HSP 90-alpha-binding agent with promising antiglaucoma activity

The Arizona Biomedical Research Commission prepares novel EGFR-based peptides

Astellas Pharma reflects on accomplishments of fiscal 2011

New biomarker for measuring disease severity in patients with diabetic retinopathy

StarGen gene therapy being tested in phase I/II clinical trial

German team discloses novel voltage-gated potassium channel modulators

Ono Pharmaceutical recaps events of fourth quarter 2011

Biota Scientific Management prepares new antiviral agents

Researchers at Merck & Co. report new series of phosphodiesterase 10A inhibitors

Blood glucose-lowering agents patented by Daiichi Sankyo

Novel IL-17 production inhibitors synthesized by Japanese group

Novelos Therapeutics provides update on HOT radiotherapeutic agent

Theraclone Sciences reports topline phase I TCN-032 study data

FDA approves TG Therapeutics' IND for phase I/II ublituximab study

Celsion and Philips Healthcare resubmit IND for ThermoDox combination study

NIDA grant supports Scripps Research Institute smoking cessation research

Cardiac function improves in preclinical study of PLX cells

ACH-3102 receives FDA fast track designation for the treatment of HCV

Phase I/IIa trial begins for Aes-103 in sickle cell disease

GSK to acquire Cellzome

Innova Biosciences awarded grant to develop nanoparticle products

Phase I/II trials begins of combination therapy for advanced metastatic melanoma

Juventas opens enrollment in phase IIa study of JVS-100

Medtronic's Resolute Integrity stent receives approval in new indications in Europe

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...